DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study

The role of adjuvant therapy following resection of biliary tract cancer (BTC) remains unclear. We therefore evaluated the feasibility and toxicity of adjuvant gemcitabine in patients with BTC. This clinical phase II trial was an open-label, single center, single-arm study. Within 8 weeks after gros...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Sang Myung, Yoon, Kyong-Ah, Hong, Eun Kyung, Park, Weon Seo, Han, Sung-Sik, Park, Sang-Jae, Joo, Jungnam, Park, Eun Young, Lee, Ju Hee, Kim, Yun-Hee, Kim, Tae Hyun, Lee, Woo Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655294/
https://www.ncbi.nlm.nih.gov/pubmed/29113399
http://dx.doi.org/10.18632/oncotarget.19037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655294/
https://www.ncbi.nlm.nih.gov/pubmed/29113399
http://dx.doi.org/10.18632/oncotarget.19037

Ejemplares similares